Please use this identifier to cite or link to this item: http://hdl.handle.net/10637/15069

Ex vivo rabbit cornea diffusion studies with a soluble insert of moxifloxacin


See/Open:
 Ex_Sebastian_DDTR_2018.pdf
  Restricted Access
1,11 MB
Adobe PDF
 Request a copy
See/Open:
 Ex_Sebastian_DDTR_2018.JPG
69,96 kB
JPEG
Title: Ex vivo rabbit cornea diffusion studies with a soluble insert of moxifloxacin
Authors : Sebastián Morelló, María
Calatayud Pascual, María Aracely
Rodilla Alama, Vicente
Balaguer Fernández, Cristina
López Castellano, Alicia Cristina
Keywords: OftalmologíaOphthalmologyDrugsMedicamentoBacteriaTratamiento médicoMedical treatment
Publisher: Springer Nature
Controlled Release Society
Citation: Sebastián-Morelló, M., Calatayud-Pascual, M.A., Rodilla, V., Balaguer-Fernández, C. & López-Castellano, A. (2018). Ex vivo rabbit cornea diffusion studies with a soluble insert of moxifloxacin. Drug Delivery and Translational Research, vol. 8, i. 1, pp. 132–139. DOI: https://doi.org/10.1007/s13346-017-0443-y
Abstract: The objective of this research was to develop and evaluate an ocular insert for the controlled drug delivery of moxifloxacin which could perhaps be used in the treatment of corneal keratitis or even bacterial endophthalmitis. We have evaluated the ex vivo ocular diffusion of moxifloxacin through rabbit cornea, both fresh and preserved under different conditions. Histological studies were also carried out. Subsequently, drug matrix inserts were prepared using bioadhesive polymers. The inserts were evaluated for their physicochemical parameters. Ophthalmic ex vivo permeation of moxifloxacin was carried out with the most promising insert. The formulate insert was thin and provided higher ocular diffusion than commercial formulations. Ocular diffusion studies revealed significant differences between fresh and frozen corneas. Histological examinations also showed differences in the thickness of stroma between fresh and frozen corneas. The ophthalmic insert we have developed allows a larger quantity of moxifloxacin to permeate through the cornea than existing commercial formulations of the drug. Ocular delivery of moxifloxacin with this insert could be a new approach for the treatment of eye diseases.
Description: Este recurso no está disponible en acceso abierto por política de la editorial.
URI: http://hdl.handle.net/10637/15069
Rights : http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
ISSN: 2190-393X
2190-3948 (Electrónico)
Issue Date: 2018
Center : Universidad Cardenal Herrera-CEU
Appears in Collections:Dpto. Farmacia





Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.